- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02614755
An Observational Study of Lumosity in Seniors
Study Overview
Status
Conditions
Detailed Description
Approximately 200 prospective users currently will be provided free 6-month premium access Lumosity accounts. Participants will be provided with an account activation code and instructed on how to sign up for Lumosity with their email address. They will be subject to the Lumosity Terms of Service and follow the typical user experience. Upon creating an account, users would be asked to complete a short demographic survey that includes questions on gender, education, occupation, years since retirement, health, computer familiarity, and perceptions of brain training.
Those who sign up will have immediate access to the Lumosity training system and the entire suite of Lumosity games. In addition, they will be invited, via email, to take the Brain Performance Test one week after the initial sign-up and then again 12 weeks later. Approximately every 8 weeks, users will be asked to complete a short questionnaire about their experience with Lumosity. This questionnaire will be accessed via email. Participants will be asked to train 5 days a week for 20-30 minutes per day, but are free to play as much or a little as they choose. Community associates at the sites will be encouraged to host group training sessions, giving the seniors a chance to gather and complete their training together, share their experiences, and get any help they may need. In addition, sites will have the option of hosting 1-2 focus groups with participants and researchers from Lumos Labs. The focus groups will be an opportunity to give and receive direct feedback about Lumosity, and get any questions answered by the researchers.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94105
- Lumos Labs, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Participants must meet the following criteria:
- 55 years of age or older
- English-speaker
- Cognitively stable (i.e., without a known diagnosis that may affect cognitive abilities)
- Regular access to and ability to use a computer or mobile device with Internet connectivity.
Exclusion Criteria:
- Under 55 years of age
- Have a current diagnosed cognitive or neuropsychological condition
- Are taking medication that may impede cognitive functioning
- Anticipate a dosage change in medication that may affect cognitive functioning during the course of the study (24 weeks)
- Have other conditions or problems that may preclude regular computer usage
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Usability - as measured by self-report feedback surveys
Time Frame: Change from Baseline - collected at baseline, 3 months and 6 months
|
Using self-report surveys administered to participants at baseline, 3 months and 6 months, investigators will calculate a usability score of Lumosity.
|
Change from Baseline - collected at baseline, 3 months and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
User Engagement - as measured by number of unique days played
Time Frame: 6 months
|
Calculating the number of unique days played will allow us to estimate the engagement level of study participants.
|
6 months
|
Change from baseline on the Lumosity Performance Index (LPI)
Time Frame: Change from Baseline - collected at baseline and 6 months
|
To evaluate the Lumosity Performance Index (LPI) results in a group of seniors
|
Change from Baseline - collected at baseline and 6 months
|
Change from baseline on the Brain Performance Test (BPT)
Time Frame: Change from Baseline - collected at baseline, 3 months and 6 months
|
To evaluate the Brain Performance Test (BPT) results in a group of seniors
|
Change from Baseline - collected at baseline, 3 months and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Glenn Morrison, PhD, Lumos Labs
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- LL004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States